CASTLE BIOSCIENCES INC (CSTL) Stock Fundamental Analysis
NASDAQ:CSTL - US14843C1053 - Common Stock
22.28 USD
+0.93 (+4.36%)
22.28 USD
0 (0%)
Overall CSTL gets a fundamental rating of 5 out of 10. We evaluated CSTL against 101 industry peers in the Health Care Providers & Services industry. No worries on liquidiy or solvency for CSTL as it has an excellent financial health rating, but there are worries on the profitability. CSTL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CSTL had positive earnings in the past year.
CSTL had a positive operating cash flow in the past year.
In the past 5 years CSTL reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: CSTL reported negative operating cash flow in multiple years.
1.2 Ratios
CSTL has a Return On Assets (-1.74%) which is comparable to the rest of the industry.
CSTL's Return On Equity of -2.08% is in line compared to the rest of the industry. CSTL outperforms 48.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.74% | ||
| ROE | -2.08% | ||
| ROIC | N/A |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CSTL's Profit Margin has been stable in the last couple of years.
CSTL's Operating Margin has declined in the last couple of years.
CSTL has a better Gross Margin (81.00%) than 94.06% of its industry peers.
CSTL's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CSTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81% |
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
CSTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
CSTL has more shares outstanding than it did 1 year ago.
CSTL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CSTL is higher compared to a year ago.
2.2 Solvency
CSTL has an Altman-Z score of 4.74. This indicates that CSTL is financially healthy and has little risk of bankruptcy at the moment.
CSTL has a Altman-Z score of 4.74. This is amongst the best in the industry. CSTL outperforms 81.19% of its industry peers.
CSTL has a debt to FCF ratio of 0.30. This is a very positive value and a sign of high solvency as it would only need 0.30 years to pay back of all of its debts.
CSTL has a Debt to FCF ratio of 0.30. This is amongst the best in the industry. CSTL outperforms 93.07% of its industry peers.
CSTL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CSTL's Debt to Equity ratio of 0.02 is amongst the best of the industry. CSTL outperforms 84.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.3 | ||
| Altman-Z | 4.74 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
CSTL has a Current Ratio of 6.85. This indicates that CSTL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CSTL (6.85) is better than 96.04% of its industry peers.
A Quick Ratio of 6.69 indicates that CSTL has no problem at all paying its short term obligations.
CSTL has a Quick ratio of 6.69. This is amongst the best in the industry. CSTL outperforms 96.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.85 | ||
| Quick Ratio | 6.69 |
3. Growth
3.1 Past
CSTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 357.14%, which is quite impressive.
CSTL shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 29.69% yearly.
CSTL shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.41%.
CSTL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 44.95% yearly.
EPS 1Y (TTM)357.14%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-51.61%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-0.94%
3.2 Future
CSTL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -32.79% yearly.
CSTL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.31% yearly.
EPS Next Y-395.59%
EPS Next 2Y-123.55%
EPS Next 3Y-70.43%
EPS Next 5Y-32.79%
Revenue Next Year-3.92%
Revenue Next 2Y-2.24%
Revenue Next 3Y1.25%
Revenue Next 5Y4.31%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 61.89, the valuation of CSTL can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as CSTL.
CSTL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.14.
The Forward Price/Earnings Ratio is negative for CSTL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.89 | ||
| Fwd PE | N/A |
4.2 Price Multiples
CSTL's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CSTL is cheaper than 78.22% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CSTL is valued a bit cheaper than 68.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.71 | ||
| EV/EBITDA | 8.24 |
4.3 Compensation for Growth
CSTL's earnings are expected to decrease with -70.43% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)2.08
EPS Next 2Y-123.55%
EPS Next 3Y-70.43%
5. Dividend
5.1 Amount
CSTL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.28
+0.93 (+4.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.95%
Inst Owner Change4.53%
Ins Owners2.76%
Ins Owner Change4.49%
Market Cap646.34M
Analysts88
Price Target36.34 (63.11%)
Short Float %4.98%
Short Ratio2.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.82%
Min EPS beat(2)-175.74%
Max EPS beat(2)128.1%
EPS beat(4)3
Avg EPS beat(4)183.56%
Min EPS beat(4)-175.74%
Max EPS beat(4)558.79%
EPS beat(8)7
Avg EPS beat(8)146.14%
EPS beat(12)10
Avg EPS beat(12)99.67%
EPS beat(16)12
Avg EPS beat(16)80.49%
Revenue beat(2)2
Avg Revenue beat(2)12.85%
Min Revenue beat(2)7.37%
Max Revenue beat(2)18.34%
Revenue beat(4)4
Avg Revenue beat(4)8.59%
Min Revenue beat(4)3.31%
Max Revenue beat(4)18.34%
Revenue beat(8)8
Avg Revenue beat(8)13.11%
Revenue beat(12)12
Avg Revenue beat(12)10.99%
Revenue beat(16)16
Avg Revenue beat(16)10.02%
PT rev (1m)-0.74%
PT rev (3m)-7.07%
EPS NQ rev (1m)15.34%
EPS NQ rev (3m)-13.02%
EPS NY rev (1m)23.37%
EPS NY rev (3m)-22.39%
Revenue NQ rev (1m)5.85%
Revenue NQ rev (3m)4.17%
Revenue NY rev (1m)7%
Revenue NY rev (3m)7.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.89 | ||
| Fwd PE | N/A | ||
| P/S | 1.87 | ||
| P/FCF | 18.71 | ||
| P/OCF | 10.34 | ||
| P/B | 1.42 | ||
| P/tB | 1.84 | ||
| EV/EBITDA | 8.24 |
EPS(TTM)0.36
EY1.62%
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)1.19
FCFY5.34%
OCF(TTM)2.15
OCFY9.67%
SpS11.94
BVpS15.7
TBVpS12.11
PEG (NY)N/A
PEG (5Y)2.08
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.74% | ||
| ROE | -2.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81% | ||
| FCFM | 9.97% |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.3 | ||
| Debt/EBITDA | 0.44 | ||
| Cap/Depr | 65.78% | ||
| Cap/Sales | 8.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 321.49% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.85 | ||
| Quick Ratio | 6.69 | ||
| Altman-Z | 4.74 |
F-Score4
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)113.65%
Cap/Depr(5y)290.73%
Cap/Sales(3y)6.28%
Cap/Sales(5y)6.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)357.14%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-51.61%
EPS Next Y-395.59%
EPS Next 2Y-123.55%
EPS Next 3Y-70.43%
EPS Next 5Y-32.79%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-0.94%
Revenue Next Year-3.92%
Revenue Next 2Y-2.24%
Revenue Next 3Y1.25%
Revenue Next 5Y4.31%
EBIT growth 1Y-46.28%
EBIT growth 3YN/A
EBIT growth 5Y3.5%
EBIT Next Year-26.07%
EBIT Next 3Y-123.63%
EBIT Next 5Y-26.67%
FCF growth 1Y166.87%
FCF growth 3YN/A
FCF growth 5Y43.14%
OCF growth 1Y254.44%
OCF growth 3YN/A
OCF growth 5Y56%